

ME THERAPEUTICS HOLDINGS INC.

177 Robson Street
Vancouver, BC V6B 0N3
Telephone: 236.516.7714

NOTICE OF ANNUAL GENERAL MEETING

TO THE SHAREHOLDERS:

NOTICE IS HEREBY GIVEN that the annual general meeting (the “**Meeting**”) of shareholders of ME Therapeutics Holdings Inc. (the “**Company**”) will be held at the offices of DLA Piper (Canada) LLP at 1133 Melville Street, Suite 2700, Vancouver, BC V6E 4E5 on Thursday, March 27, 2025, at the hour of 10:00 a.m. (Vancouver time) for the following purposes:

- (1) to receive the audited financial statements of the Company for the fiscal year ended August 31, 2024, and the accompanying report of the auditors;
- (2) to set the number of directors of the Company for the ensuing year at four (4);
- (3) to elect Dr. Salim Zulifkar Dhanji, Dr. John Priatel, Dr. Kenneth Harder and Karim Nanji as directors of the Company;
- (4) to appoint Davidson & Company LLP as the auditors of the Company for the fiscal year ending August 31, 2025 and to authorize the directors of the Company to fix the remuneration to be paid to the auditors for the fiscal year ending August 31, 2025; and
- (5) to transact such further or other business as may properly come before the Meeting and any adjournment or postponement thereof.

The accompanying Information Circular provides additional information relating to the matters to be dealt with at the Meeting and is supplemental to, and expressly made a part of, this notice of Meeting (the “**Notice of Meeting**”).

The board of directors of the Company has fixed February 10, 2024 as the record date for the determination of shareholders entitled to notice of and to vote at the Meeting and at any adjournment or postponement thereof. Each registered shareholder at the close of business on that date is entitled to such notice and to vote at the Meeting in the circumstances set out in the accompanying Information Circular.

If you are a registered shareholder of the Company and unable to attend the Meeting in person, please vote by proxy by following the instructions provided in the form of proxy at least 48 hours (excluding Saturdays, Sundays and holidays recognized in the Province of British Columbia) before the time and date of the Meeting or any adjournment or postponement thereof.

Notice-and-Access

The Company has elected to use the notice and access (“**Notice and Access**”) provisions under National Instrument 54-101 *Communications with Beneficial Owners of Securities of a Reporting Issuer* and National Instrument 51-102 *Continuous Disclosure Obligations* to distribute Meeting materials to shareholders. Notice and Access allows issuers to post electronic versions of proxy related materials on SEDAR+ and on one additional website, rather than mailing paper copies to shareholders. Shareholders have the right to request hard copies of any proxy related materials posted online by the Company under Notice and Access.

Meeting materials, including the Circular, are available under the Company's profile at www.sedarplus.com and also at www.metherapeutics.com. The Company will provide to any shareholder, free of charge, upon request to the Company's transfer agent, Odyssey Trust Company ("**Odyssey Trust**") at 1-888-290-1175 (toll-free within North America) or 1-587-885-0960 (direct from outside North America), a paper copy of the Circular and any financial statements or management's discussion and analysis of the Company filed with the applicable securities regulatory authorities during the past year. In order to allow reasonable time for you to receive and review a paper copy of the Circular or other document prior to the proxy deadline, you should make your request for a paper copy to Odyssey Trust by February 25, 2025.

Shareholders will have the opportunity to participate at the Meeting via the Microsoft Teams link below. Additionally, shareholders can participate via teleconference by calling +1 604-901-0719. Callers should dial in fifteen to twenty minutes prior to the scheduled time of the Meeting and input conference code 689812823# to join the Meeting. Please refer to the sections titled "Appointment of Proxyholders", "Voting of Shares and Proxies and Exercise of Discretion by Designated Persons", "Advice to Beneficial Shareholders" and "Revocation of Proxies" in the Circular for details on how to vote at the Meeting. **Shareholders will not be able to vote through the Microsoft Teams link or by teleconference. We encourage shareholders to vote their Common Shares prior to the Meeting by any of the means described in the Circular.**

The Microsoft Teams Meeting ID and passcode below has been provided to enable Shareholders to participate in the Meeting:

Meeting ID: 252 707 160 679

Passcode: EG3p7TK3

Link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_NDUzNzA2NWUtODVlYy00YzUwLTlmYtEtOTI3YmQyMGZiNW5%40threid.v2/0?context=%7b%22Tid%22%3a%22b925436f-dc0f-4783-9a0e-ebd3680ae995%22%2c%22Oid%22%3a%22988e9270-422e-4e05-b6cf-53cbec04ae53%22%7d

The conference number below has been provided to enable Shareholders to participate in a voice only conference call for the Meeting:

Dial in: +1 604-901-0719 Canada, Vancouver

Dial in: +1 587-774-8973 Canada, Calgary

Phone Conference ID: 689 812 823#

Only shareholders whose names have been entered in the register of shareholders at the close of business on February 10, 2025, the record date for the Meeting, will be entitled to receive notice of and to vote at the Meeting. A registered shareholder may attend the Meeting in person or may be represented by proxy. Shareholders who are unable to attend the Meeting or any adjournment or postponement thereof in person are requested to date, sign and return the accompanying form of proxy for use at the Meeting or any adjournment or postponement thereof. To be effective, the enclosed form of proxy must be deposited with the Company's registrar and transfer agent, Odyssey Trust., by mail or delivery to United Kingdom Building, 350 – 409 Granville Street, Vancouver BC V6C 1T2 301, Attn: Proxy Department, no later than 10:00 a.m. (Vancouver time) on March 25, 2025, being at least 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) before any adjournment or postponement of the Meeting.

If you are a non-registered shareholder of the Company and received this Notice of Meeting and accompanying materials through a broker, a financial institution, a participant, or a trustee or administrator of a retirement savings plan, retirement income fund, education savings plan or other similar savings or investment plan registered

under the Income Tax Act (Canada), or a nominee of any of the foregoing that holds your securities on your behalf (each, an “**Intermediary**”), please complete and return the materials in accordance with the instructions provided to you by your Intermediary.

DATED at Vancouver, British Columbia, this 10th day of February, 2025.

By Order of the Board of Directors of

ME THERAPEUTICS HOLDINGS INC.

“Salim Zulifkar Dhanji”

Dr. Salim Zulifkar Dhanji

Chief Executive Officer and Director

PLEASE VOTE. YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, SIGN AND DATE THE ENCLOSED FORM OF PROXY AND PROMPTLY RETURN IT IN THE ENVELOPE PROVIDED.